Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Completed · Not applicable

Conditions studied: Hematologic Malignancies

In brief

The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic stem cell transplant.

Key facts

Study ID

NCT00741455

Run by

Dartmouth-Hitchcock Medical Center

People needed

18

Starts

2004-06-01

Expected to finish

2020-05-01

Last updated by the study team

2020-11-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: 18-75 years
• Diseases
• Chronic myelogenous leukemia (CML)
• First chronic phase or later
• Accelerated phase
• Acute myelogenous or lymphoblastic leukemia (AML or ALL)
• Second or subsequent remission
• Patients who have failed an autologous PBSC transplant
• First remission with poor risk features, including, but not limited to: For AML- complex chromosome karyotype, abnormalities of chromosome 5 or 7, 12p-, 13+, 8+, t(9;22), t(11;23) For ALL- t(9;22), t(4;11), t(1;19), myeloid antigen coexpression
• Myelodysplastic syndrome (MDS)
• Multiple myeloma - high risk myeloma (poor responders, relapse after autologous PBSCT, chromosome 13 abnormalities)
• Hodgkin's disease
• Primary refractory disease
• Relapsed disease (first relapse or later)
• Patients who have failed an autologous PBSC transplant
• Non-Hodgkin's lymphoma Low grade (by Working Formulation)
• Relapsed, progressive disease after initial chemotherapy
• Primary refractory disease or failure to respond (>PR) to initial chemotherapy
• Patients who have failed an autologous PBSC transplant Intermediate grade (by Working Formulation)
• Relapsed disease
• Primary refractory disease or failure to respond (>PR) to initial chemo
• Mantle cell lymphoma
• Patients who have failed an autologous PBSC transplant
• Chronic lymphocytic leukemia (CLL)
• Patients newly diagnosed with poor prognostic factors, including CD38 expression, Chromosome 11 or 17 abn

You may not qualify if…

• Major organ dysfunction
• Pregnant or lactating female
• Active infection
• Psychological problems that preclude compliance and completion of the clinical trial
• Any other condition, that in the judgement of the investigator, affects participant safety or overall participation

Where it is running

• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.